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We read with interest the article by Ham et al., which investigates whether dividing Gleason 
score (GS) 8-10 disease into GS 8 and GS 9-10 provides prognostic information regarding mor-
tality (1). We sought to validate their findings of increased hazards in GS 9-10 compared to GS 8 
across other prostate cancer (PC) cohorts with long-term follow-up.  
 
We leveraged data from men of the Health Professionals Follow-up Study and the Physicians’ 
Health Study who were treated by radical prostatectomy (RP) over the period 1983-2009. Of 
1,395 men, 279 (20%) scored as GS 8-10. In the GS 8 group (n=108), 18 lethal or metastatic 
events were observed over a median of 10.2 years follow-up. In the GS 9-10 group (n=171), 37 
events were observed over a median of 9.2 years follow-up. The hazard ratio (HR) comparing GS 
9-10 to GS 8 was 1.34 (95% CI: 0.74-2.36; p=0.31). The association was similar when adjusted 
for pathologic stage and age, with HR 1.39 (95% CI: 0.71-2.71). Analogous results emerged from 
545 men who underwent RP over the years 1987-2001 at the Mayo clinic (2). Among 211 men 
with GS 8-10, the odds ratio for lethal or metastatic disease comparing GS 9-10 to GS 8 was 1.21 
(95% CI: 1.06-1.39; p=0.01). 
 
Taken together, our analyses suggest that, while the trend of higher mortality in the GS 9-10 
compared to GS 8 persists, the prostate cancer-specific HR may be less than the estimate derived 
from the Johns Hopkins cohort, 2.38 (95% CI: 1.74-3.28). Discrepancies in our point estimates 
compared to those of Johns Hopkins may arise because of several reasons. First, approximately 
8.9% of all men in the Johns Hopkins cohort (2006 to 2016) suffered from GS 8-10 (3). However 
in the current study only 1047 men which represent only 4.3% were included in the final analysis. 
Therefore around 1100 (4.6%) men were excluded because “incomplete clinicopathologic or fol-
low-up data”, or a “history of neoadjuvant treatment”. Second, in our and the Mayo cohort but 
not in the Johns Hopkins cohorts, all RP specimens were rereviewed by study pathologists to 
assign standardized GS. Third, the median follow-up is distinct between the Johns Hopkins co-
hort (4 years), our cohort (10 years) and the mayo cohort (17 years). To summarize, we assume 
certain patient selection in the study by Ham et al. which may led to the observed HR. 
 
More broadly, an elevated HR alone as a measure of prognostic accuracy may be incongruous 
with clinical utility. Specifically, it is possible for markers to have a large effect on the hazard of 
death, yet exhibit poor performance discriminating those patients who have lethal cancers from 
those that do not (4). The latter goal is of elevated importance in clinical decision making, and 
future analyses that explore the benefit of GS subdivisions on sensitivity, specificity, and predic-
tive values could help clarify their role. We look forward to such studies and, in the meantime, we 
commend the authors for their insightful and impactful work in this area to date. 
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